Sartorius Stedim Biotech Reveals Preliminary 2024 Financial Results

Sartorius Stedim Biotech reported preliminary, unaudited financial results for 2024, highlighting stable sales revenue at 2,780 million euros, a slight rise of 0.6% in constant currencies. The underlying EBITDA stood at 779 million euros, with a margin of 28.0%, aligning with the company's targets. The net profit was 175 million euros, reflecting a cautious optimism for 2025 with expectations of profitable growth.

The second half of 2024 saw a significant uptick in order intakes, rising by 12.9% in constant currencies. Regional performance varied; while EMEA and Asia Pacific experienced growth, the Americas faced a downturn. Despite challenges like inventory destocking, Sartorius recorded robust competitiveness, particularly in consumables and advanced therapies.

Equity increased substantially due to a successful capital raise, with a net operating cash flow of 815 million euros, aiding strategic debt reduction. Looking ahead, Sartorius anticipates recovery and growth but remains cautious regarding long-term market trends.